10 Stocks With Massive Losses; AI Stocks Not Spared

Page 9 of 9

1. Exelixis, Inc. (NASDAQ:EXEL)

Exelixis tumbled by 12 percent on Monday to close at $34.54 apiece as unimpressed investors soured on the results of its phase 3 trial for the study of Zanzalintinib for colon cancer.

In an updated report, Exelixis, Inc. (NASDAQ:EXEL) said the drug candidate—Zanzalintinib, in combination with atezolizumab—improved median overall survival to 10.9 months versus 9.4 months with regorafenib, significantly reducing the risk of death by 20 percent in the intention-to-treat population.

“While treating non-MSI-high metastatic colorectal cancer remains a challenge, the combination of zanzalintinib and atezolizumab has shown consistent benefits across key subgroups of patients,” said University of Pittsburgh Section Chief of Gastrointestinal Oncology Anwaar Saeed.

Exelixis, Inc. (NASDAQ:EXEL) EVP for Research and Development Dana Aftab said that the results from the latest clinical trial provide further insight into the combination of zanzalintinib and atezolizumab “as a potential new option” to extend survival in patients with the said type of cancer.

While we acknowledge the potential of EXEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EXEL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9